Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Janssen

Showing results (131-140 of 1,929) with videos related to

Pageof 193
Sort By:
The New England Journal of Medicine|January 8, 2025
Combination Therapy for Chronic HBV InfectionHarry L A Janssen, Milan J Sonneveld
Journal of Hepatology|December 1, 2024
Reply to: "The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients"Edo J Dongelmans, Harry L A Janssen
Plos One|July 18, 2015
Costs of Planned Home vs. Hospital Birth in British Columbia Attended by Registered Midwives and PhysiciansPatricia A Janssen, Craig Mitton, Jaafar Aghajanian
Scandinavian Journal of Infectious Diseases. Supplementum|January 1, 1982
Treatment of helminthiasisP A Janssen, H van den Bossche
Water Science and Technology : a Journal of the International Association on Water Pollution Research|October 4, 2002
Optimisation of control of river and sewage flows in the Great Culvert, EnglandR H A Janssen, S M Mills
Experimental & Applied Acarology|August 13, 2002
Predatory mites avoid ovipositing near counterattacking preyF Faraji, A Janssen, M W Sabelis
Environmental Modelling & Software : with Environment Data News|September 22, 2020
On code sharing and model documentation of published individual and agent-based modelsMarco A Janssen, Calvin Pritchard, Allen Lee
The New England Journal of Medicine|August 22, 2006
Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2Sarwa Darwish Murad, Harry L A Janssen
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2011
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?Milan J Sonneveld, Harry L A Janssen
Journal of Hepatology|March 13, 2026
Is Partial Cure a Realistic Endpoint for Novel Hepatitis B Therapy? Reply to Chan et alMilan J Sonneveld, Harry L A Janssen
Pageof 193

Showing results (131-140 of 1,929) with videos related to

Sort By:
Pageof 193
The New England Journal of Medicine|January 8, 2025
Combination Therapy for Chronic HBV InfectionHarry L A Janssen, Milan J Sonneveld
Journal of Hepatology|December 1, 2024
Reply to: "The incidence of hepatitis flare and hepatic decompensation after nucleos(t)ide analogue cessation in chronic hepatitis B patients"Edo J Dongelmans, Harry L A Janssen
Plos One|July 18, 2015
Costs of Planned Home vs. Hospital Birth in British Columbia Attended by Registered Midwives and PhysiciansPatricia A Janssen, Craig Mitton, Jaafar Aghajanian
Scandinavian Journal of Infectious Diseases. Supplementum|January 1, 1982
Treatment of helminthiasisP A Janssen, H van den Bossche
Water Science and Technology : a Journal of the International Association on Water Pollution Research|October 4, 2002
Optimisation of control of river and sewage flows in the Great Culvert, EnglandR H A Janssen, S M Mills
Experimental & Applied Acarology|August 13, 2002
Predatory mites avoid ovipositing near counterattacking preyF Faraji, A Janssen, M W Sabelis
Environmental Modelling & Software : with Environment Data News|September 22, 2020
On code sharing and model documentation of published individual and agent-based modelsMarco A Janssen, Calvin Pritchard, Allen Lee
The New England Journal of Medicine|August 22, 2006
Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2Sarwa Darwish Murad, Harry L A Janssen
Liver International : Official Journal of the International Association for the Study of the Liver|January 6, 2011
Chronic hepatitis B: peginterferon or nucleos(t)ide analogues?Milan J Sonneveld, Harry L A Janssen
Journal of Hepatology|March 13, 2026
Is Partial Cure a Realistic Endpoint for Novel Hepatitis B Therapy? Reply to Chan et alMilan J Sonneveld, Harry L A Janssen
Pageof 193